0RY Stock Overview
A medical diagnostics company, provides blood tests for the detection of cancers in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rhythm Biosciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.035 |
| 52 Week High | AU$0.20 |
| 52 Week Low | AU$0.027 |
| Beta | 2.65 |
| 11 Month Change | -4.05% |
| 3 Month Change | -10.13% |
| 1 Year Change | -80.62% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RY | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -4.1% | -3.2% | -0.007% |
| 1Y | -80.6% | 0.003% | 6.8% |
Return vs Industry: 0RY underperformed the German Healthcare industry which returned 0% over the past year.
Return vs Market: 0RY underperformed the German Market which returned 6.8% over the past year.
Price Volatility
| 0RY volatility | |
|---|---|
| 0RY Average Weekly Movement | 12.0% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0RY has not had significant price volatility in the past 3 months.
Volatility Over Time: 0RY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Atkins | rhythmbio.com |
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Limited Fundamentals Summary
| 0RY fundamental statistics | |
|---|---|
| Market cap | €9.25m |
| Earnings (TTM) | -€4.18m |
| Revenue (TTM) | €1.03m |
9.0x
P/S Ratio-2.2x
P/E RatioIs 0RY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RY income statement (TTM) | |
|---|---|
| Revenue | AU$1.69m |
| Cost of Revenue | AU$3.05m |
| Gross Profit | -AU$1.36m |
| Other Expenses | AU$5.50m |
| Earnings | -AU$6.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | -80.31% |
| Net Profit Margin | -405.69% |
| Debt/Equity Ratio | 0% |
How did 0RY perform over the long term?
See historical performance and comparison